Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

There are currently no items available.

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
11/20/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/20/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/17/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/13/174Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/08/1710-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
11/14/17Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
PARSIPPANY, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that its supplemental New Drug Application (sNDA) for EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block for regional analgesia will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC).  The meeting is tentatively scheduled for February 14-15, 2... 
Printer Friendly Version
11/09/17Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences: Jefferies 2017 Healthcare Conference in London, on Thursday, November 16, 2017 at 10:00 AM GMT (5:00 AM ET) Piper Jaffray 29th Annual Healthcare Conference in New York City, on Wednesday, November 29, 2017 at 10:00 AM ET A live audio webcast of the Pacira presentation... 
Printer Friendly Version
11/08/17Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
EXPAREL(R) net product sales of $66.8 million up 3% over prior year third quarter; Full-year EXPAREL net product sales guidance revised to $280 to $285 million; Conference Call Today at 8:30 a.m. ET PARSIPPANY, NJ -- (Marketwired) -- 11/08/17 -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2017. "We continue to make important progress during 2017 as we advance our strategy to expand the ro... 
Printer Friendly Version
10/31/17Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday November 8, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialin... 
Printer Friendly Version
10/25/17Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement
Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair PARSIPPANY, N.J. and MALVERN, Pa., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has committed to invest up to $25 million in TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex™ portfolio of products for ventral hernia repair and abdom... 
Printer Friendly Version
10/18/17Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia
PARSIPPANY, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration via nerve block for prolonged regional analgesia. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is April 6, 2018. ... 
Printer Friendly Version
09/27/17Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
PARSIPPANY, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chairman and chief executive officer, will testify this afternoon before President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis. The Commission, led by New Jersey Governor Chris Christie, was created to study ways to combat and treat drug abuse, addiction and the opioid crisis. The meeting, which will be held in Washington, D.C. today from ... 
Printer Friendly Version
09/26/17New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk
Patients receive an average of 85 pills following surgery; overprescribing leads to 3.3 billion unused postsurgical opioids every year An Analysis of the Impact of Opioid Overprescribing in America Middle-aged and Generation X women have highest rates of p... 
Printer Friendly Version
09/20/17Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
PARSIPPANY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Cantor Fitzgerald Global Healthcare Conference at 10:20 AM ET on Tuesday, September 26, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archiv... 
Printer Friendly Version
09/13/17Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent PARSIPPANY, N.J., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced a collaboration with Aetna, one of the nation’s leading diversified health care benefits companies, with the support of the American Association of Oral and Maxillofacial Surgeons (AAOMS), on a national program aimed at reducing the number of opioid tablets prescribe... 
Printer Friendly Version
>> Access Older Press Releases

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...